Condition: Haemophagocytic Lymphohistiocytosis · Sponsor: Assistance Publique - Hôpitaux de Paris
The purpose of this project is to study the survival of patients until Haematopoietic Stem Cell Transplantation following the use of Ruxolitinib as first-line treatment associated to corticosteroids in primary HLH.
This description comes directly from the study's public registry record.
Despina MOSHOUS, MD, PhD · 01 44 49 48 23 · despina.moshous@aphp.fr
Laure CHOUPEAUX · 01 44 38 17 11 · laure.choupeaux@aphp.fr
Always discuss trial participation with your own doctor first.
| Hopital Necker Enfants malades | Paris, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05762640